Summary of the technology
A new alternative treatment for steatohepatitis has been developed; it consisits on new series of amides of fatty acids with fenilalquilamines (amphetamines, dopamine, etc.) A new mechanism of action based in reductions of consumption is exploded: activation of reduce intake and oxidative stress antagonism.
New and innovative aspects
The properties of the amides are: - PPAR alpha activation with major affinity to fibrates, what warrants deep lipid-lowering effects and metabolism activators. - Fatty liver deposit decrease. Inhibition of the SCD1 enzyme expression (desaturase 1), a fundamental mechanism in hepatic steatosis. -Capability of decrease the intake, thus antiobesity profile is added to its antiesteatosic profile.
Main advantages of its use
The benefits of its use are the following: - New therapeutic entities for one of the most prevalent metabolic diseases. - Small molecules easy to synthesize. - Its compounds are accepted by Lipinsky rule’s. - Safe Pharmacological profile not interact with hERG, and has no or moderate effects on the activity of various hepatic cytochrome P450.
In in vivo trials realized, both chronic and acute, have demonstrate evidence of activity against steatohepatitis, showing a decrease in liver level of plasma triglycerides. Furthermore, tests show renal functions improvement through a reduction in plasmatic levels of increased of urea and hepatic transaminase in plasma with a fall of ALT and AST
- Metabolic diseases and endocrinology
Current development status
In use, testing results avalaible
Desired business relationship
About IMIM Institut Recerca Hospital del Mar
Research & Technology Organization from SpainIMIM Institut Recerca Hospital del Mar
IMIM (Hospital del Mar Medical Research Institute), located at the Barcelona Biomedical Research Park (PRBB) is, up to 82%, made up of research groups lead by professionals from the MAR Health Park , most of whom are associates of the Autonomous University of Barcelona (UAB) and the Pompeu Fabra University (UPF), as well as other seconded staff members from the Centre for Research in Environmental Epidemiology (CREAL), the Centre for Genomic Regulation (CRG), the Department of Experimental and Health Sciences of the Pompeu Fabra University (DCEXS-UPF), the Centre of Regenerative Medicine in Barcelona (CMRB) and the Barcelona Biomedical Research Park (PRBB). On 16 December 2013, the Accreditation Committee of the Carlos III Health Institute (ISCIII) approved the acreditation of IMIM as a Health Research Institute, which was ratified by the State Secretarial of Research, Development and Innovation for the Order of 17 February 2014. At IMIM there are around seven hundred professionals, of which one hundred and nineteen are lead researchers distributed in fifty-six research groups integrated into the five multi-disciplinary programmes framing research activities within IMIM: Cancer, directed by Joan Albanell Epidemiology and Public Health, directed by Jordi Alonso Cardiovascular and inflammatory processes, directed by Miguel López-Botet Biomedical Informatics, directed by Ferran Sanz Neurosciences, directed by Rafael de la Torre A large proportion of its budget is provided by external competitive funds that are managed by the Mar Institute of Medical Research Foundation. The scientific output generate from this research includes almost 550 annual papers in international journals indexed in the Science Citation Index (SCI). Another relevant fact is that 65% of the IMIM papers are published in journals that are in the top quartile of their category. IMIM has a Scientific Advisory Board (SAB) made up of a group of prestigious international expert scientists from the different areas of the IMIM research programmes.